KRAS Antibody: FITC

KRAS, a well-characterized oncogene encoding a small GTPase, is emerging as a critical player in neurodegenerative disease research. Traditionally studied in cancer biology, KRAS regulates key cellular processes such as proliferation, differentiation, and survival through the MAPK/ERK and PI3K/AKT pathways. Recent studies suggest that dysregulation of KRAS signaling may contribute to neuronal vulnerability, synaptic dysfunction, and neuroinflammation—hallmarks of disorders like Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) . In the central nervous system, KRAS is expressed in neurons and glial cells, where it modulates neurodevelopmental signaling and cellular stress responses. Aberrant KRAS activity has been linked to impaired autophagy, mitochondrial dysfunction, and altered neurotrophic signaling, all of which are implicated in progressive neurodegeneration. Moreover, KRAS-mediated pathways intersect with tau phosphorylation and amyloid precursor protein processing, positioning KRAS as a potential upstream regulator of pathogenic cascades. Understanding KRAS function in neural contexts opens new avenues for therapeutic intervention. Targeting KRAS or its downstream effectors may offer neuroprotective strategies, particularly in early-stage disease. As neuroscience increasingly intersects with molecular oncology, KRAS represents a promising biomarker and mechanistic bridge between cancer biology and neurodegeneration.

KRAS, KRAS1, KRAS2, K-Ras 2, K RAS2A, K RAS2B, K RAS4A, K RAS4B, Ki-Ras, c-Ki-ras, c-K-ras, cK Ras, cK-ras, RASK2, RASK_HUMAN, NS3, NS, p21ras, K RAS p21 protein, GTPase KRas, Transforming protein p21, Oncogene KRAS2, Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog, Cellular c Ki ras2 proto oncogene, PR310 cK ras oncogene, KIRSTEN MURINE SARCOMA VIRUS 2